Repositioning Candidate Details
| Candidate ID: | R0288 |
| Source ID: | DB00981 |
| Source Type: | approved; investigational |
| Compound Type: | small molecule |
| Compound Name: | Physostigmine |
| Synonyms: | |
| Molecular Formula: | C15H21N3O2 |
| SMILES: | [H][C@]12N(C)CC[C@@]1(C)C1=C(C=CC(OC(=O)NC)=C1)N2C |
| Structure: |
|
| DrugBank Description: | A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity. |
| CAS Number: | 57-47-6 |
| Molecular Weight: | 275.3461 |
| DrugBank Indication: | For the treatment of glaucoma, and in the treatment of severe anticholinergic toxicity. |
| DrugBank Pharmacology: | Physostigmine is a parasympathomimetic, specifically, a reversible cholinesterase inhibitor which effectively increases the concentration of acetylcholine at the sites of cholinergic transmission. Physostigmine is used to treat glaucoma. Because it crosses the blood-brain barrier, it is also used to treat the central nervous system effects of atropine overdose and other anticholinergic drug overdoses. Physostigmine can reverse both central and peripheral anticholinergia. |
| DrugBank MoA: | Physostigmine inhibits acetylcholinesterase, the enzyme responsible for the breakdown of used acetylcholine. By interfering with the metabolism of acetylcholine, physostigmine indirectly stimulates both nicotinic and muscarinic receptors due to the consequential increase in available acetylcholine at the synapse. |
| Targets: | Acetylcholinesterase; Neuronal acetylcholine receptor subunit alpha-4; Neuronal acetylcholine receptor subunit beta-2 |
| Inclusion Criteria: |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|